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Abstract : Breast cancer is increasing in the elderly.  Although elderly breast 
cancer patients frequently receive less invasive therapy, its appropriateness is 
debatable.  Ki-67 expression is a controversial prognostic factor and predictor 
of the efcacy of postoperative adjuvant therapy.  This study investigated the 
value of the Ki-67 labeling index （LI） in elderly breast cancer patients, espe-
cially with respect to adjuvant therapy.  This retrospective study investigated 
82 primary breast cancer patients aged ≥ 70 years who underwent surgery 
between 1995 and 2005.  Their clinicopathological ndings were reviewed and 
their Ki-67 LIs were determined.  The patients’ mean age was 78 years, the 
mean observation period was 53.8 months, and 60 patients （73.2%） underwent 
adjuvant therapy.  The St. Gallen （2007） risk category and the Ki-67 LI 
（mean, 15.3%） were both signicantly correlated with relapse and prognosis. 
In the 31 cases with a low Ki-67 LI （＜10%）, 1 patient who underwent adju-
vant treatment relapsed, but there were no deaths.  Among the intermediate- 
and high-risk patients, Ki-67 was low in 15 ; 1 patient who underwent adjuvant 
treatment relapsed, but there were no deaths.  For elderly breast cancer 
patients aged ≥ 70 years categorized low risk by St. Gallen （2007） or with 
a low Ki-67 LI, the risk of relapse and death appears to be low regardless 
of adjuvant therapy.  Though further investigation is needed to determine a 
method of measuring the Ki-67 LI and determining a cut-off value, our nd-
ings suggest that the Ki-67 LI helps with the selection of adjuvant therapy in 
elderly patients.
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Introduction
　In Japan, primary breast cancer has the highest age-adjusted incidence of all cancers 
affecting women, and the number of affected individuals is increasing1）.  Breast cancer is 
also increasing in the elderly because of improved life expectancy.  According to a nation-
wide survey of breast cancer patients by the Japanese Breast Cancer Society, the proportion 
of breast cancer patients aged 70 years or over was 18.4% in 2004, and had increased to 
19.2% by 2007.  In many cases, elderly breast cancer patients have underlying diseases 2-4）. 
Their underlying disease status and degree of activity in daily living need to be taken into 
account for treatment.  Therefore, less invasive treatment is often chosen.  However, lack of 
clear evidence supporting such an approach makes this choice debatable.
　At present, adjuvant therapy for primary breast cancer is often performed in Japan with 
reference to the St. Gallen Consensus Conference.  Risk categories were adopted at the 
2007 St. Gallen conference and age was included as one of the evaluation factors 5）.  How-
ever, prognosis standards for elderly breast cancer patients are inconclusive.  In contrast, 
an increase in treatment-related deaths has been reported among the elderly 6）, and certain 
standards have been formulated for adjuvant therapy.
　At the 2009 St. Gallen conference, evaluation of the tumor proliferation potential was 
included as a criterion for chemotherapy 7）.  In recent years, the expression of the tumor 
proliferation potential marker Ki-67 （Ki-67 labeling index ［Ki-67 LI］） has been a strong 
candidate for a prognostic factor and a predictor of the efcacy of adjuvant therapy 8-12）. 
While broad consensus on its use as a prognostic factor has been obtained, its use as an 
effective predictor of postoperative adjuvant therapy is still controversial.  In addition, there 
have been recent studies examining the correlation between Ki-67 LI and the need for 
adjuvant therapy in the elderly.
　This retrospective study investigated cases of primary breast cancer surgery in patients 
aged ≥ 70 years, with each patient being classied into a St. Gallen （2007） risk category. 
After identifying Ki-67 as a potential marker of tumor proliferation, the correlation between 
postoperative adjuvant therapy and relapse and prognosis was examined, and patients not 
requiring therapy were identied.
Materials and Methods
　A total of 92 patients aged ≥ 70 years underwent surgery for primary breast cancer at 
the Showa University Hospital and Toyosu Hospital, Showa University School of Medicine 
between 1995 and 2005.  From these 92 patients, 10 patients were excluded because of 
ductal carcinoma in situ （6 patients）, heterochronous bilateral breast cancer （2 patients）, 
and preoperative chemotherapy （2 patients）; the remaining 82 patients were included in 
this retrospective study.  We reviewed the histopathological ndings of these 82 patients and 
examined the relationship with their relapse status and prognosis.
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　An automated staining method was used to calculate the Ki-67 LI in each tumor sample 
（Ventana HX BenchMark System, Ventana Medical Systems, Inc., Tucson, Arizona）.  The 
samples were deparafnized and washed with water, and then heat-activated using EDTA. 
For primary antibody, a 50×dilution of Ki-67 monoclonal antibody （MIB-1 ; DAKO, 
Glostrup, Denmark） was used （reaction time, 32 minutes）.  The LI was determined using 
an optical microscope and examination under 400×magnication in three randomly selected 
elds.  Two hundred tumor cells were counted in each, and the proportion of positive nuclei 
per 600 tumor cells was calculated （Fig. 1）.
　We also examined the expression of the estrogen receptor （ER）, progesterone receptor 
（PgR）, and human epidermal growth factor receptor 2 （HER2） in each tumor, and assessed 
the risk category according to the St. Gallen conference （2007）.  Statistical analyses were 
performed using the χ2 test and a P-value of ＜ 0.05 was deemed signicant.
Results
　The mean patient age was 78 years （range, 70-97 years）, the mean observation period 
was 53.8 months （range, 2-124 months）, and 60 of the 82 patients （73.2%） underwent adju-
vant therapy.  There were 14 deaths in the study population, of which 7 were due to other 
causes : 3 from malignant tumors in other organs, 1 from acute myocardial infarction, 1 from 
acute subdural hematoma, 1 from pneumonia, and 1 from chronic heart failure.  This study 
only investigated the prognosis for the present illness.
　Pathological characteristics are listed in Table 1. Scirrhous carcinoma was the most repre-
sented histological type, with 46 cases （56.1%）.  Special types included 3 cases （3.7%） of 
mucinous carcinoma, 2 （2.4%） of invasive lobular carcinoma, and 1 （1.2%） of apocrine car-
cinoma.  Immunohistochemistry revealed that 61 cases （74.4%） were ER-positive, 46 cases 
（56.1%） were PgR-positive, and 12 cases （14.6%） were HER2-positive.
Fig. 1.  Example of Ki-67 staining
Tumor cells with positive nuclei were counted, even 
if the staining was slight.
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　Based on the St. Gallen risk categories of 2007, 27 patients （39.2%） were classed as 
low risk, 42 （51.2%） as intermediate risk, and 13 （15.9%） as high risk.  The correlations 
between each of these categories and relapse and prognosis were examined （Table 2）.  The 
Table 1.  Patient histopathology
histological 
type
scirrhous 46 56（%）
solid-tubular 14 17（%）
papillo-tubular 16 20（%）
mucinous 3 4（%）
invasive-lobular 2 2（%）
apocrine 1 1（%）
tumor
size
T1 46 56（%）
T2 29 35（%）
T3  7  9（%）
nuclear
grade
1 47 62（%）
2 13 17（%）
3 16 21（%）
vessel
invasion
（-） 58 70（%）
（＋） 24 30（%）
lymph node 
metastasis
0 48 68（%）
1-3 15 21（%）
4  8 11（%）
ER （-） 21 26（%）
（＋） 61 74（%）
PgR （-） 36 44（%）
（＋） 46 56（%）
HER2 （-） 70 85（%）
（＋） 12 15（%）
Table 2.  Correlation between relapse or prognosis and various factors
total
relapse prognosis
（-） （＋） p-value survival death p-value
tumor size T1 46 40 6
p＝ 0.15
43 3
p＝ 0.72T2 29 23 6 26 3
T3  7  4 3  6 1
nuclear
grade
1 47 45 2
p＜ 0.001
（＊）
46 1
p＝ 0.022
（＊）2 13 7 6 10 3
3 16 9 7 13 3
vessel 
invasion
（-） 58 52 6 p＝ 0.0038
（＊）
57 1 p＜ 0.001
（＊）（＋） 24 15 9 18 6
lymph node 
metastasis
0 48 45 3
p＜ 0.001
（＊）
46 2
p＜ 0.001
（＊）1-3 15 12 4 15 0
4  8  2 6  4 4
ER （-） 21 13 8 p＝ 0.006
（＊）
18 3
p＝ 0.027
（＋） 61 54 7 57 4
PgR （-） 36 25 11 p＝ 0.01
（＊）
32 4
p＝ 0.46
（＋） 46 42 4 43 3
HER2 （-） 70 59 11
p＝ 0.14
64 6
p＝ 0.98
（＋） 12  8 4 11 1
St. Gallen 
risk category
（2007）
low 27 27 0
p＜ 0.001
（＊）
27 0
p＜ 0.001
（＊）intermediate 42 35 7 39 3
high 13  5 8  9 4
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risk category was signicantly correlated with relapse （P＝ 0.00001）.  In addition, nuclear 
grade, the presence of vascular invasion, lymph node metastasis, ER-positive expression, and 
PgR-positive expression showed signicant correlations with relapse.  The risk category was 
also signicantly correlated with prognosis （P＝ 0.004）.  Furthermore, signicant correlations 
were observed between prognosis and nuclear grade and the presence of vascular invasion.
　Relapse and prognosis with and without adjuvant therapy are summarized by risk cat-
egory in Table 3.  Of the 27 patients categorized as low risk, 13 did not undergo adjuvant 
therapy.  Regardless of whether they underwent adjuvant therapy, there were no relapses or 
deaths among the 27 low-risk patients.
　The mean Ki-67 LI was 15.3%.  The Ki-67 LI of each patient was plotted against relapse 
and prognosis （Fig. 2）.  Because no deaths were observed in patients with a Ki-67 LI of 
less than 10%, the study was performed by setting the Ki-67 cut-off value at 10%.  The 
associations between the Ki-67 LI and various factors are listed in Table 4.  The Ki-67 LI 
Table 3.  Relapse and prognosis with and without adjuvant therapy, by risk category
adjuvant 
therapy
relapse（＋） relapse（-） death survival
low risk
（-） 0/12（ 0％） 12/12（100％） 0/12（ 0％） 12/12（100％）
（＋） 0/15（ 0％） 15/15（100％） 0/15（ 0％） 15/15（100％）
intermediate risk
（-） 1/9 （11％）  8/9 （ 89％） 0/9 （ 0％）  9/9 （100％）
（＋） 6/33（18％） 27/33（ 82％） 3/33（ 9％） 30/33（ 91％）
high risk
（-） 0/0 （ 0％）  0/0 （　0％） 0/0 （ 0％）  0/0 （　0％）
（＋） 8/13（62％）  5/13（ 38％） 4/13（31％）  9/13（ 69％）
Fig. 2.  Ki-67 and relapse, and prognosis
The values of the Ki-67 labeling indexes （Ki-67 LIs） were plotted 
according to relapse and prognosis. Because no deaths were observed 
in patients with a Ki-67 LI＜ 10%, the study was performed by setting 
the Ki-67 cut-off value at 10%.
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was signicantly correlated with tumor size, nuclear grade, the presence of vascular invasion, 
ER-positive expression, PgR-positive expression, HER2-positive expression, risk category, 
relapse, and prognosis.
　Relapse and prognosis with and without adjuvant therapy are summarized by the Ki-67 
LI in Table 5-1.  In the 31 patients with a low Ki-67 LI, 1 patient who underwent adjuvant 
treatment relapsed, but there were no deaths.  Of the intermediate- and high-risk patients 
in this group （Table 5-2）, the Ki-67 LI was low in 15 patients.  Of these, 1 patient who 
underwent adjuvant treatment relapsed, but there were no deaths.
Discussion
Characteristics of breast cancer in the elderly
　Histopathology
　Scattered reports have indicated a high incidence of special-type carcinomas, especially 
Table 4.  Correlation between Ki-67 and various factors
total
Ki-67 LI
＜ 10％
Ki-67 LI
≥ 10％ p-value
tumor size T1 46 23 23
p＝ 0.032
（＊）T2 29 7 22
T3  7 1  6
nuclear
grade 
1 47 23 24
p＝ 0.029
（＊）2 13 4  9
3 16 2 14
vessel
invasion
（-） 58 28 30 p＝ 0.002
（＊）（＋） 24  3 21
lymph node 
metastasis
0 48 19 29
p＝ 0.721-3 15 6 9
4  8 2 6
ER （-） 21 2 19 p＝ 0.002
（＊）（＋） 61 29 32
PgR （-） 36  7 29 p＝ 0.002
（＊）（＋） 46 24 22
HER2 （-） 70 31 39 p＝ 0.003
（＊）（＋） 12  0 12
St. Gallen 
risk category 
（2007）
low 27 16 11
p＝ 0.011
（＊）intermediate 42 13 29
high 13  2 11
relapse （-） 67 30 37 p＝ 0.001
（＊）（＋） 15  1 14
prognosis （-） 75 31 44 p＝ 0.031
（＊）（＋）  7  0  7
159Signicance of Ki-67 Expression and Risk Category
mucinous and apocrine carcinomas, as a pathological feature of breast cancer in the 
elderly13）.  Furthermore, other reports have demonstrated increases in invasive lobular carci-
noma14）.  In this study, mucinous carcinoma was the most commonly occurring special type 
of carcinoma, at about 4%.  In addition, many reports have indicated that ER-positive cases 
are common in the elderly 2, 3, 13, 14）, they accounted for about 74% of the cases in this study, 
a similar frequency to that reported in the literature.
　Prognosis
　Past studies of breast cancer in the elderly reported high rates of malignancy and poorer 
prognoses than in young patients 3）.  However, it has been shown that a higher proportion 
of elderly patients has underlying diseases and they succumb from other causes 2, 3）.  Further-
more, elderly patients often present to the doctor later than young patients, and they are 
given treatment protocols that are less invasive, even in cases with a high risk of relapse 15）. 
These factors may inuence prognosis in the elderly.  In a study of 1568 people aged ≥ 55 
years at the MD Anderson Cancer Center 4）, nonstandard surgical treatments and adjuvant 
hormonal therapy and chemotherapy for breast cancer patients aged ≥ 75 years made simple 
comparisons difficult.  Lately, a growing number of cases are being diagnosed relatively 
early among the elderly, and excluding deaths from other causes, reports of prognoses are 
relatively good 14）, though other reports state that there is still no less risk of relapse16）.
　Therapy for breast cancer in the elderly
　Many opinions on postoperative chemotherapy in the elderly advise a cautious approach. 
Muss et al 6） reported that, while a certain effect can be gained from chemotherapy, there 
are signicantly higher numbers of treatment-related deaths in those aged ≥ 65 years.  In 
contrast, some reports urge chemotherapy for patients with hormone receptor-negative lymph 
node metastasis17）.  In a 15-year, randomized controlled trial by the Early Breast Cancer 
Table 5-1.  Relapse and prognosis with or without adjuvant therapy, by Ki-67 LI
Ki-67 LI relapse（＋） death
adjuvant
therapy
（-）
＜ 10％  0/10（ 0％） 0/10（ 0％）
≥ 10％  1/11（ 9％） 0/11（ 0％）
（＋）
＜ 10％  1/21（ 5％） 0/21（ 0％）
≥ 10％ 13/50（26％） 7/50（14％）
Table 5-2.   Relapse and prognosis with or without adjuvant therapy, by Ki-67 LI 
（intermediate to high risk）
Ki-67 LI relapse（＋） death
adjuvant
therapy
（-）
＜ 10％  0/1 （ 0％） 0/1 （ 0％）
≥ 10％  1/8 （ 9％） 0/8 （ 0％）
（＋）
＜ 10％  1/14（ 7％） 0/14（ 0％）
≥ 10％ 13/32（41％） 7/32（22％）
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Trialists’ Collaborative Group, few patients aged ≥ 70 years received postoperative chemo-
therapy and so no clear conclusions could be drawn for this age group15）.
　The Early Breast Cancer Trialists’ Collaborative Group study also reported that tamoxifen 
was considered an effective hormonal therapy after surgery for all ages15）.  On the other 
hand, large-scale trials such as the Arimidex, Tamoxifen, Alone or in Combination trial18） 
and the Breast International Group trial 1-9819） reported that an aromatase inhibitor was 
more useful than tamoxifen even in elderly patients, and they recommended aggressive 
hormone treatment of hormone receptor-positive patients, even in the elderly.
　However, there have also been reports that hormone therapy does not improve the 
prognosis of patients without lymph node metastases 20）, and adjuvant treatment of low-risk 
patients is still subject to debate.  According to the American Society of Clinical Oncology’s 
2009 consensus 21）, aromatase inhibitors are not recommended for low-risk patients of any 
age.
Ki-67 immunohistochemical staining
　Characteristics of Ki-67
　Ki-67 is a human nuclear antigen which is associated with all cell nuclei during the pro-
liferating cell cycle except for the G0 phase 22）.  In 1983, Gerdes and colleagues 23） developed 
a monoclonal antibody against Ki-67 from Hodgkin’s disease-derived cells, and Ki-67 is 
now widely used as a biological marker for determining the tumor proliferation potential 
In recent years it has attracted attention as a prognostic factor and predictor of efcacy of 
adjuvant therapy in breast cancer.  Reports on the connection with prognosis have been 
particularly numerous 8, 9）, and a near-consensus on this has been reached.  The Ki-67 LI 
was also signicantly correlated with relapse and prognosis in the present study.
　Determination of the Ki-67 labeling index
　Ki-67 immunostaining using parafn staining is widespread at present, but the LI is not 
determined in any consistent way.  Jones et al 24） reported that 400×magnification in 10 
elds, counting at least 1000 tumor cells, is essential.  However, this method is complex and 
time-consuming in actual clinical practice, so some facilities use automated measurements 
assisted by analysis software8）, and this technique is also reported to be useful for needle 
biopsy tissue 25）.  However, this automated technique tends to count some nontumor cells, 
such as lymphocytes, thus affecting its accuracy.  In the present study, as a simple, accurate 
measuring technique, a visual count of 600 tumor cells in three random fields was per-
formed.
　Mitotic count and Ki-67
　Originally, the mitotic count in the sample was used to determine the nuclear grade with 
respect to the tumor proliferation potential.  As mentioned earlier, because Ki-67 stains the 
cell nuclei in all growth phases except during the G0 phase, the results do not agree with 
the mitotic count.  However, they should be correlated, and this has been substantiated by 
161Signicance of Ki-67 Expression and Risk Category
many reports 26, 27）.  In contrast, Jalava et al 28） examined prognoses classied into subgroups 
by mitotic count and the Ki-67 LI, and they observed that the prognosis for a high mitotic 
count was poor even when the Ki-67 LI was low.  St. Gallen （2009） observed that either 
the Ki-67 LI or the mitotic count can be used for evaluation of the tumor proliferation 
potential, and as an example of a Ki-67 LI cut-off value, enumerated 30% of that used by 
Jalava et al 7）.
　Ki-67 as a predictor
　Several large-scale trials have reported differing results regarding the signicance of the 
Ki-67 LI as a predictor of efcacy of adjuvant therapy.  The Breast International Group 
trial 1-98 8） indicated excellent disease-free survival （DFS） for patients with a high Ki-67 LI 
（＞ 11%） in the group treated with letrozole in a tamoxifen and letrozole comparison trial 
involving 4922 patients.  In a Breast Cancer International Research Group trial 10）, hormone 
receptor-positive, HER2-negative breast cancer patients were classied by the Ki-67 LI into 
luminal A （ ≤ 11%） and luminal B （ ＞ 11%） subtypes.  In addition, FAC （uorouracil, 
doxorubicin, and cyclophosphamide） and TAC （docetaxel, doxorubicin, and cyclophospha-
mide） treatment groups were compared.  DFS was signicantly improved in the luminal B 
subtype in the TAC treatment group.
　The International Breast Cancer Study Group trial looked at both premenopausal and 
postmenopausal patients 9）.  In both cases, hormone therapy alone and hormone therapy 
with CMF （cyclophosphamide, methotrexate, and uorouracil） were compared.  The Ki-67 
LI was included as an item of consideration （cut-off value 19%）, but it was not considered 
a predictor of efcacy of CMF either pre- or post-menopause.
　Unfortunately the drugs used were different in each of these investigations, and because 
of the connection between adjuvant therapy and the Ki-67 LI, the differences in results 
are likely due to the different treatment regimes.  Thus, each individual treatment needs a 
separate study.  In any event, no conclusions have yet been reached on the signicance of 
the Ki-67 LI as a predictor of efcacy of adjuvant therapy after surgery.  St. Gallen （2009） 
adopted evaluation of the tumor proliferation potential as a criterion for chemotherapy after 
surgery 7）, but in the American Society of Clinical Oncology guidelines, Ki-67 is not recog-
nized as a routine biological marker 29）, so there is a difference of opinion.
　Furthermore, in recent years there has been a focus on the change in Ki-67 before and 
after preoperative therapy.  The Immediate Preoperative Anastrozole, Tamoxifen, or Com-
bined with Tamoxifen study reported that, over the 2 weeks after preoperative hormone 
therapy, the Ki-67 LI was correlated with DFS 30）.  In addition, Jones et al 31） reported the 
Ki-67 LI in samples resected during surgery after preoperative chemotherapy to be a prog-
nostic factor 31）.  Thus, it is becoming standard to examine the Ki-67 LI after preoperative 
treatment.
　Problems with Ki-67
　Many studies investigating a correlation between Ki-67 and prognosis have been reported, 
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but their methods of determination and evaluation have not been consistent.  Apart from 
the count method described above, consensus is also needed on whether the determination 
region of the specimen should be the most-stained region or a random region, and on what 
degree of staining is considered positive.  The cut-off value is also not well established, and 
reports to date have used a wide range of cut-off values, from 1% to 40%.  Ki-67 is likely 
to have great clinical usefulness, and further investigation is warranted.
Conclusions
　This was a retrospective investigation, and we leave decisions pertaining to the details 
of hormone therapy and chemotherapy to the clinicians.  However, at least among elderly 
breast cancer patients aged ≥ 70 years, categorized as low risk by St. Gallen （2007）, or 
intermediate or high risk with a low Ki-67 LI, the risks of relapse and death regardless of 
adjuvant therapy are believed to be low, suggesting the possibility of abbreviating adjuvant 
therapy.
　Further investigation is needed to determine a standard method of measuring the Ki-67 
LI and a cut-off value.  In addition, studies specic to the various adjuvant therapy regimes 
are also essential.
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